Spyre Therapeutics, Inc. (SYRE) Balance Sheet
SYRE balance sheet, 2025
December 31, 2025 · U.S. dollars$777.8M assets = $62.5M liabilities + $715.2M equity
Both columns are drawn to the same scale: what SYRE owns equals what it owes plus shareholders’ equity. Hover a block for its value.
SYRE financial health
Equity / assets92.0%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles0.0%
Mostly tangible · of total assets
Descriptive bands, not a rating. Fiscal 2025.
SYRE balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $67.1M2016 | $777.8M2025 | +31.3%/yr | |
| Total liabilities | $4.1M2016 | $62.5M2025 | +35.4%/yr | |
| Shareholders’ equity | $63.0M2016 | $715.2M2025 | +31.0%/yr | |
| Cash & short-term investments | $63.5M2016 | $756.5M2025 | +31.7%/yr | |
| Total debt | $5.1M2019 | $84.6M2024 | +75.2%/yr | |
| Net cash (debt) | $66.8M2019 | $518.5M2024 | +$451.7M | |
| Working capital | $62.5M2016 | $719.1M2025 | +$656.6M | |
| Book value per share | $11.012024 | $11.172025 | +1.4%/yr | |
| Debt / equity | 0.092019 | 0.162024 | +0.08 | |
| Shares outstanding | 47.0M2024 | 64.1M2025 | +36.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SYRE assets
Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current
SYRE liabilities and equity
Current liabilitiesLong-term debtOther long-term liabilitiesEquity
SYRE debt vs cash
Total debtCash & ST investmentsNet cash (debt)
Debt includes short- and long-term borrowings and, where reported, lease obligations.
SYRE balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $756.5M | $603.1M | $339.3M | $55.7M | $93.1M | $146.3M | $71.9M | $74.5M | $50.3M | $63.5M |
| Cash & equivalents | $85.7M | $89.4M | $188.9M | $34.9M | $15.1M | $90.1M | $19.3M | $22.5M | $12.8M | $47.7M |
| Short-term investments | $670.8M | $513.7M | $150.4M | $20.8M | $78.0M | $56.2M | $52.7M | $52.1M | $37.5M | $15.8M |
| Receivables | $0 | $0 | $0 | $375,000 | $815,000 | $0 | $0 | $300,000 | $3.1M | $1.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $21.2M | $5.4M | $2.3M | $6.2M | $4.9M | $3.5M | $2.6M | $1.9M | $1.6M | $1.7M |
| Total current assets | $777.8M | $608.5M | $341.5M | $62.3M | $98.9M | $149.8M | $74.5M | $76.7M | $55.0M | $66.4M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $6.7M | $8.4M | $9.9M | $7.2M | $1.0M | $854,000 | $599,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $10,000 | $331,000 | $2.2M | $2.7M | $2.0M | $1.5M | $50,000 | $232,000 | $40,000 |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M | $161.6M | $83.2M | $77.7M | $56.1M | $67.1M |
| Liabilities | ||||||||||
| Accounts payable | $8.9M | $666,000 | $896,000 | $677,000 | $3.3M | $2.3M | $3.2M | $663,000 | $389,000 | $168,000 |
| Short-term debt | — | — | — | $625,000 | $436,000 | $319,000 | $379,000 | — | — | — |
| Deferred revenue | — | — | — | $517,000 | $2.4M | $13.4M | — | — | $20,000 | $71,000 |
| Total current liabilities | $58.7M | $54.1M | $32.0M | $14.7M | $20.1M | $16.4M | $18.4M | $10.2M | $5.6M | $4.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | $0 | $4.6M | $5.1M | $5.4M | $5.1M | — | — | — |
| Other long-term liabilities | $3.9M | $36.6M | $125.9M | $6.2M | $5.8M | $5.3M | $4.7M | $72,000 | $111,000 | $132,000 |
| Total liabilities | $62.5M | $90.7M | $157.8M | $20.8M | $26.0M | $21.8M | $23.1M | $10.3M | $5.7M | $4.1M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $15,000 | $13,000 | $10,000 | $6,000 | $5,000 | $5,000 | $3,000 | $2,000 | $2,000 | $1,000 |
| Retained earnings (deficit) | −$1.13B | −$972.4M | −$764.4M | −$425.6M | −$341.8M | −$276.0M | −$195.1M | −$116.9M | −$72.5M | −$45.3M |
| Accumulated other comprehensive income | $869,000 | $180,000 | $302,000 | −$48,000 | −$20,000 | $11,000 | $51,000 | −$27,000 | −$102,000 | −$4,000 |
| Total shareholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M | $139.8M | $60.1M | $67.4M | $50.3M | $63.0M |
| Key figures | ||||||||||
| Total debt | — | $84.6M | $84.6M | $4.6M | $5.1M | $5.4M | $5.1M | — | — | — |
| Net cash (debt) | — | $518.5M | $254.7M | $51.1M | $88.1M | $140.8M | $66.8M | — | — | — |
| Working capital | $719.1M | $554.4M | $309.6M | $47.6M | $78.7M | $133.3M | $56.1M | $66.4M | $49.4M | $62.5M |
| Tangible book value | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M | $139.8M | $60.1M | $67.4M | $50.3M | $63.0M |
| Book value per share | $11.17 | $11.01 | — | — | — | — | — | — | — | — |
| Shares outstanding | 64.1M | 47.0M | — | — | — | — | — | — | — | — |
| Current ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 | 9.11 | 4.06 | 7.49 | 9.77 | 16.75 |
| Quick ratio | 12.89 | 11.16 | 10.61 | 3.83 | 4.66 | 8.90 | 3.92 | 7.31 | 9.48 | 16.32 |
| Debt / equity | — | 0.16 | 0.46 | 0.09 | 0.06 | 0.04 | 0.09 | — | — | — |
| Equity / assets | 92.0% | 85.1% | 53.8% | 70.7% | 76.4% | 86.5% | 72.2% | 86.7% | 89.8% | 93.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.15B | $741.5M | $756.5M | $486.2M | $526.6M | $564.8M | $603.1M | $414.2M | $426.0M | $484.6M | $339.3M | $203.6M |
| Cash & equivalents | $162.0M | $97.2M | $85.7M | $64.9M | $81.7M | $48.5M | $89.4M | $71.6M | $45.1M | $227.6M | $188.9M | $90.6M |
| Short-term investments | $983.3M | $644.3M | $670.8M | $421.3M | $444.9M | $516.3M | $513.7M | $342.6M | $380.9M | $257.1M | $150.4M | $113.0M |
| Receivables | $0 | $4.6M | $0 | $3.6M | $3.5M | $0 | $0 | $0 | $0 | $0 | $0 | $163,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $27.7M | $17.9M | $21.2M | $14.8M | $8.8M | $4.9M | $5.4M | $6.9M | $9.7M | $2.6M | $2.3M | $2.2M |
| Total current assets | $1.17B | $764.0M | $777.8M | $504.6M | $538.8M | $569.8M | $608.5M | $421.1M | $435.7M | $487.3M | $341.5M | $205.9M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $10,000 | $10,000 | $10,000 | $331,000 | $329,000 | $331,000 | $1.3M |
| Total assets | $1.17B | $764.0M | $777.8M | $504.6M | $538.8M | $569.8M | $608.5M | $421.1M | $436.1M | $487.6M | $341.9M | $207.3M |
| Liabilities | ||||||||||||
| Accounts payable | $5.7M | $5.7M | $8.9M | $7.5M | $3.7M | $3.7M | $666,000 | $5.2M | $3.2M | $3.1M | $896,000 | $1.7M |
| Total current liabilities | $63.3M | $85.2M | $58.7M | $46.3M | $83.1M | $70.7M | $54.1M | $57.5M | $22.1M | $42.8M | $32.0M | $44.9M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | — | — | — | — | — | $0 | $0 |
| Other long-term liabilities | $8.6M | $8.0M | $3.9M | $3.2M | $0 | $16.5M | $36.6M | $36.2M | $39.6M | $292.5M | $125.9M | $407.8M |
| Total liabilities | $71.9M | $93.1M | $62.5M | $49.5M | $83.1M | $87.2M | $90.7M | $93.7M | $61.7M | $335.3M | $157.8M | $452.7M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $16,000 | $15,000 | $15,000 | $13,000 | $13,000 | $13,000 | $13,000 | $12,000 | $12,000 | $10,000 | $10,000 | $7,000 |
| Retained earnings (deficit) | −$1.23B | −$1.20B | −$1.13B | −$1.07B | −$1.05B | −$1.02B | −$972.4M | −$916.1M | −$847.1M | −$808.3M | −$764.4M | −$701.2M |
| Accumulated other comprehensive income | −$2.4M | −$767,000 | $869,000 | $791,000 | $454,000 | $682,000 | $180,000 | $1.5M | −$553,000 | −$363,000 | $302,000 | −$132,000 |
| Total shareholders' equity | $1.10B | $670.8M | $715.2M | $455.1M | $455.8M | $482.6M | $517.8M | $327.4M | $374.4M | $152.3M | $184.0M | −$245.4M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | — | — | — | — | $253.4M | $84.6M | $387.1M |
| Net cash (debt) | — | — | — | — | — | — | — | — | — | $231.2M | $254.7M | −$183.5M |
| Working capital | $1.11B | $678.8M | $719.1M | $458.3M | $455.8M | $499.1M | $554.4M | $363.5M | $413.6M | $444.5M | $309.6M | $161.1M |
| Tangible book value | $1.10B | $670.8M | $715.2M | $455.1M | $455.8M | $482.6M | $517.8M | $327.4M | $374.4M | $152.3M | $184.0M | −$245.4M |
| Book value per share | $13.00 | $8.54 | $9.53 | $7.53 | $7.51 | $8.01 | $11.01 | $6.43 | $8.26 | $4.17 | $8.48 | — |
| Shares outstanding | 84.7M | 78.5M | 75.1M | 60.4M | 60.7M | 60.3M | 47.0M | 50.9M | 45.3M | 36.5M | 21.7M | — |
| Current ratio | 18.53 | 8.97 | 13.25 | 10.90 | 6.49 | 8.06 | 11.26 | 7.32 | 19.70 | 11.38 | 10.68 | 4.59 |
| Quick ratio | 18.09 | 8.76 | 12.89 | 10.58 | 6.38 | 7.99 | 11.16 | 7.20 | 19.26 | 11.32 | 10.61 | 4.54 |
| Debt / equity | — | — | — | — | — | — | — | — | — | 1.66 | 0.46 | — |
| Equity / assets | 93.9% | 87.8% | 92.0% | 90.2% | 84.6% | 84.7% | 85.1% | 77.7% | 85.9% | 31.2% | 53.8% | −118.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 19, 2026); data from EODHD.
SYRE financial position
At the end of fiscal 2025 (December 31, 2025), Spyre Therapeutics had total assets of $777.8 million (up 27.8% from a year earlier), total liabilities of $62.5 million and shareholders' equity of $715.2 million. Its current ratio was 13.25. In the latest quarter (ended June 30, 2026) total assets were $1.2 billion and equity $1.1 billion.
Related: SYRE income statement, SYRE cash flow statement, SYRE key metrics. See the SYRE stock overview for the latest quote and news.
SYRE balance sheet FAQ
What are Spyre Therapeutics's total assets?
Spyre Therapeutics reported total assets of $777.8 million at the end of fiscal 2025 (December 31, 2025), compared with $608.5 million a year earlier.
How much cash does Spyre Therapeutics have?
Spyre Therapeutics held $756.5 million in cash and short-term investments at the end of fiscal 2025.
What is Spyre Therapeutics's book value?
Spyre Therapeutics's shareholders' equity (book value) was $715.2 million at the end of fiscal 2025, or $11.17 per share.
What is Spyre Therapeutics's current ratio?
Spyre Therapeutics had current assets of $777.8 million and current liabilities of $58.7 million, a current ratio of 13.25 (it can cover its short-term obligations).